Perrigo Co plc (PRGO)

Perrigo Company plc provides over-the-counter health and wellness solutions in the United States, Europe, and internationally. The company operates through Consumer Self-Care Americas and Consumer Self-Care International segments. It offers upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and oral electrolyte beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers. The company also offers healthy lifestyle products, such as smoking cessation and well-being products; skin care products consisting of dermatological care, scar management, lice treatment, and other products for various skin conditions; women's health products comprising feminine hygiene and contraceptives; vitamins, minerals, and supplements; and other miscellaneous self-care products. It sells its products under the Compeed, Dr. Fresh, Firefly, Good Sense, Good Start, Mederma, Nasonex, Plackers, Prevacid24HR, REACH, Rembrandt, Steripod, Opill, Solpadeine, Coldrex, Physiomer, NiQuitin, ACO, ellaOne, and Compeed brands. The company also offers contract manufacturing services. It sells its products through retail drug, supermarket, and mass merchandise chains; e-commerce stores; wholesalers; pharmacies; drug and grocery retailers; and para-pharmacies. The company was formerly known as Perrigo Company and changed its name to Perrigo Company plc in December 2013. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.

Ticker
PRGO
Exchange
NYSE
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Market cap
$2.20B
52-week range
$9.23 - $16.81

Valuation

Share price
$15.85 (close of Nov 6, 2026)
P/E (TTM)
-1.24x
Price to book
0.90x
Price to free cash flow
13.08x
Enterprise value
$5.06B
Book value per share
$17.58

Price performance

PeriodChange
1 day+0.89%
5 days+0.44%
1 month+13.21%
3 months+26.40%
6 months+29.28%
Year to date+13.86%
1 year+6.16%
3 years-44.33%
5 years-65.82%
10 years-80.76%
All time+36.34%

Short interest

As of
Oct 15, 2026
Short % of float
26.72%
Shares short
24.18M
Days to cover
9.03
Change since prior report
-0.25%
Source
FINRA consolidated short interest

Profitability and growth

Return on equity
-48.56%
Return on invested capital
-17.07%
Return on assets
-16.70%
Return on capital employed
-14.92%
Gross margin
35.14%
Net margin
-33.51%
EBITDA margin
-18.45%
Revenue growth
-2.75%
Free cash flow growth
-40.68%

Cash flow and balance sheet

Free cash flow yield (TTM)
7.65%
Current ratio
2.35x
Net debt to EBITDA
-2.51x

Latest reported year

Period end
Dec 31, 2025
Fiscal year
2025
Revenue
$4.25B
Cost of revenue
$2.76B
Gross profit
$1.49B
EBITDA
-$784.70M
Net income
-$1.43B
Earnings per share
$-10.29
Research and development
$95.40M
Interest expense
$162.50M
Shares outstanding
138.50M

Income statement by year

Period endRevenueGross profitNet incomeEPS
2025-12-31$4.25B$1.49B-$1.43B-$10.29
2024-12-31$4.37B$1.54B-$171.80M-$1.25
2023-12-31$4.66B$1.68B-$12.70M-$0.09
2022-12-31$4.45B$1.46B-$140.60M-$1.04
2021-12-31$4.14B$1.42B-$68.90M-$0.52
2020-12-31$4.09B$1.49B-$162.60M-$1.20
2019-12-31$3.87B$1.43B$146.10M$1.07
2018-12-31$4.73B$1.83B$131.00M$0.95
2017-12-31$4.95B$1.98B$119.60M$0.84
2016-12-31$5.28B$2.05B-$4.01B-$28.01

Margins and returns by year

Period endGross marginNet marginReturn on equityReturn on capital
2025-12-3135.14%-33.51%-48.56%-17.07%
2024-12-3135.27%-3.93%-3.98%0.71%
2023-12-3136.09%-0.27%-0.27%1.72%
2022-12-3132.69%-3.16%-2.90%0.88%
2021-12-3134.22%-1.66%-1.34%2.31%
2020-12-3136.57%-3.98%-2.88%2.82%
2019-12-3137.05%3.78%2.52%1.87%
2018-12-3138.71%2.77%2.31%1.30%
2017-12-3140.02%2.42%1.94%4.60%
2016-12-3138.86%-75.99%-67.36%-9.90%

Cash and debt by year

Period endCashDebt
2025-12-31$531.60M$3.60B
2024-12-31$558.80M$3.58B
2023-12-31$751.30M$3.63B
2022-12-31$600.70M$4.07B
2021-12-31$1.86B$2.92B
2020-12-31$631.50M$3.53B
2019-12-31$354.30M$3.37B
2018-12-31$551.10M$3.05B
2017-12-31$678.70M$3.27B
2016-12-31$622.30M$5.22B

Free cash flow by year

Period endFree cash flowStock-based compensation
2025-12-31$145.10M$54.60M
2024-12-31$244.60M$64.40M
2023-12-31$303.80M$68.80M
2022-12-31$210.90M$54.90M
2021-12-31$4.20M$60.10M
2020-12-31$465.80M$58.50M
2019-12-31$250.10M$52.20M
2018-12-31$490.40M$37.70M
2017-12-31$610.30M$43.80M
2016-12-31$548.70M$23.00M

Dividend history

Most recent payment
Aug 28, 2026
Payment dateDividend per share
2026-08-28$0.29
2026-05-29$0.29
2026-03-02$0.29
2025-08-29$0.29
2025-05-30$0.29
2025-03-07$0.29
2024-11-29$0.28
2024-08-30$0.28

Investor relations

Past earnings dates

ReportedFiscal periodEPS estimate
2026-11-04Sep 2026$0.56
2026-08-05Jun 2026$0.31
2026-05-06Mar 2026$0.39
2026-02-26Dec 2025$0.80
2025-11-05Sep 2025$0.75
2025-08-06Jun 2025$0.59
2025-05-07Mar 2025$0.56
2025-02-27Dec 2024$0.92

Filings and sources

Company website
perrigo.com
SEC filings
10-K, 10-Q and 8-K on EDGAR
Earnings calendar
All upcoming reports

Similar companies

Teva Pharmaceutical Industries Ltd (TEVA) · Zoetis Inc. (ZTS) · Viatris Inc (VTRS) · Hims & Hers Health, Inc. (HIMS) · Haleon plc (HLN) · Thermo Fisher Scientific Inc. (TMO) · Danaher Corp (DHR) · Natera, Inc. (NTRA)

All Healthcare companies

Understanding these figures

Price-to-earnings ratio · Short interest · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart

Explore

Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades